IS6814A - Vatnsrof [R(R*,R*)]-2-(4-flúorfenýl)-ß,ð-díhýdroxý-5-(1-metýletýl)-3-fenýl-4-[(fenýlamínó)karbónýl]-1H-pýrról-1-heptanónsýruestera með kalsíumhýdroxíði - Google Patents

Vatnsrof [R(R*,R*)]-2-(4-flúorfenýl)-ß,ð-díhýdroxý-5-(1-metýletýl)-3-fenýl-4-[(fenýlamínó)karbónýl]-1H-pýrról-1-heptanónsýruestera með kalsíumhýdroxíði

Info

Publication number
IS6814A
IS6814A IS6814A IS6814A IS6814A IS 6814 A IS6814 A IS 6814A IS 6814 A IS6814 A IS 6814A IS 6814 A IS6814 A IS 6814A IS 6814 A IS6814 A IS 6814A
Authority
IS
Iceland
Prior art keywords
calcium hydroxide
dihydroxy
heptanoic acid
phenylamino
methylethyl
Prior art date
Application number
IS6814A
Other languages
English (en)
Inventor
Lidor-Hadas Rami
Lifshitz-Liron Revital
Ishai Eti
Niddam-Hildesheim Valerie
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of IS6814A publication Critical patent/IS6814A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic System
    • C07F1/06—Potassium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IS6814A 2000-11-16 2003-05-14 Vatnsrof [R(R*,R*)]-2-(4-flúorfenýl)-ß,ð-díhýdroxý-5-(1-metýletýl)-3-fenýl-4-[(fenýlamínó)karbónýl]-1H-pýrról-1-heptanónsýruestera með kalsíumhýdroxíði IS6814A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24931900P 2000-11-16 2000-11-16
US31214401P 2001-08-13 2001-08-13
US32652901P 2001-10-01 2001-10-01
PCT/US2001/050639 WO2002043667A2 (en) 2000-11-16 2001-10-24 HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE

Publications (1)

Publication Number Publication Date
IS6814A true IS6814A (is) 2003-05-14

Family

ID=27400196

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6814A IS6814A (is) 2000-11-16 2003-05-14 Vatnsrof [R(R*,R*)]-2-(4-flúorfenýl)-ß,ð-díhýdroxý-5-(1-metýletýl)-3-fenýl-4-[(fenýlamínó)karbónýl]-1H-pýrról-1-heptanónsýruestera með kalsíumhýdroxíði

Country Status (23)

Country Link
US (1) US6528661B2 (is)
EP (1) EP1341785B1 (is)
JP (1) JP4234429B2 (is)
KR (1) KR100877165B1 (is)
CN (1) CN1330644C (is)
AT (1) ATE410413T1 (is)
AU (2) AU3289102A (is)
CA (1) CA2427255A1 (is)
CZ (1) CZ20031595A3 (is)
DE (1) DE60136095D1 (is)
DK (1) DK1341785T3 (is)
ES (1) ES2313999T3 (is)
HR (1) HRP20030454A2 (is)
HU (1) HUP0303555A3 (is)
IL (1) IL155890A0 (is)
IS (1) IS6814A (is)
MX (1) MXPA03004276A (is)
NO (1) NO20032200L (is)
NZ (1) NZ526022A (is)
PL (1) PL362981A1 (is)
PT (1) PT1341785E (is)
SK (1) SK7212003A3 (is)
WO (1) WO2002043667A2 (is)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
AP1571A (en) * 2001-06-29 2006-02-10 Warner Lambert Co Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
AU2002255479B2 (en) * 2001-07-30 2008-09-11 Dr. Reddy's Laboratories Ltd. Crystalline forms VI and VII of atorvastatin clacium
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
CA2450820C (en) * 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
EP1572638A4 (en) * 2001-08-31 2010-05-05 Morepen Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS CALCIUM ATORVASTATIN SALT (2: 1)
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
BR0307303A (pt) * 2002-01-31 2005-01-11 Novartis Ag Processo para a fabricação de inibidores da hmg-coa redutase
BR0215644A (pt) 2002-03-18 2004-12-21 Biocon Ltd Inibidores de redutase de hmg-coa amorfos do tamanho de partìcula desejado
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
CN102285916B (zh) 2003-02-12 2015-02-25 日产化学工业株式会社 匹伐他汀钙的晶形
AU2003231926A1 (en) 2003-04-22 2004-11-19 Biocon Limited NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ss-KETOESTERS
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
EP1663969A1 (en) * 2003-09-17 2006-06-07 Warner-Lambert Company LLC Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
US7557238B2 (en) 2003-09-18 2009-07-07 Biocon Limited Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005063741A1 (en) * 2003-12-29 2005-07-14 Lek Pharmaceuticals D.D. Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
SI21745A (sl) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
CA2649054A1 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
EP1771455B1 (en) * 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Oxidative degradation products of atorvastatin calcium
MX2007000765A (es) 2004-07-20 2007-03-28 Warner Lambert Co Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
NZ554541A (en) 2004-10-28 2011-01-28 Warner Lambert Co Process for forming amorphous atorvastatin
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
IE20060197A1 (en) * 2005-03-14 2006-10-18 Pfizer Science & Tech Ltd Preparation of an atorvastatin intermediate
CA2621506A1 (en) * 2005-09-09 2007-03-15 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate
WO2007029217A1 (en) * 2005-09-09 2007-03-15 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
DK1957452T3 (da) 2005-11-21 2010-07-26 Warner Lambert Co Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
KR20100023059A (ko) * 2005-12-13 2010-03-03 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
CN101395132A (zh) * 2006-03-01 2009-03-25 特瓦制药工业有限公司 制备阿托伐他汀半钙的晶形的方法
WO2009082362A1 (en) * 2007-11-05 2009-07-02 Ulkar Kimya San. Ve Tic. A.S. A method for producing statins in pure form
KR100850850B1 (ko) * 2008-01-25 2008-08-06 주식회사종근당 아토르바스타틴의 제조방법 및 이에 사용되는 중간체
US11473032B2 (en) 2010-02-02 2022-10-18 Fuchs Petrolub Se Constant velocity joint having a boot
US20130041162A1 (en) * 2010-04-19 2013-02-14 Dsm Sinochem Pharmaceuticals Netherlands B.V. Production of atorvastatin low in ether impurities
WO2011131601A1 (en) * 2010-04-19 2011-10-27 Dsm Ip Assets B.V. Production of atorvastatin low in lactone impurities
JP5843406B2 (ja) 2014-02-19 2016-01-13 株式会社オートネットワーク技術研究所 金属表面コーティング用組成物およびこれを用いた端子付き被覆電線
CN104447487A (zh) * 2014-12-07 2015-03-25 河南豫辰药业股份有限公司 一种阿托伐他汀半钙的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748825C2 (de) * 1976-11-02 1986-11-27 Sankyo Co., Ltd., Tokio/Tokyo Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2450820C (en) * 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins

Also Published As

Publication number Publication date
NZ526022A (en) 2005-04-29
ES2313999T3 (es) 2009-03-16
CN1330644C (zh) 2007-08-08
EP1341785A2 (en) 2003-09-10
IL155890A0 (en) 2003-12-23
AU3289102A (en) 2002-06-11
NO20032200D0 (no) 2003-05-15
WO2002043667A2 (en) 2002-06-06
HUP0303555A2 (hu) 2004-03-01
NO20032200L (no) 2003-06-24
CZ20031595A3 (cs) 2003-11-12
JP4234429B2 (ja) 2009-03-04
US6528661B2 (en) 2003-03-04
CA2427255A1 (en) 2002-06-06
AU2002232891B2 (en) 2006-12-14
HUP0303555A3 (en) 2005-08-29
HRP20030454A2 (en) 2005-10-31
KR100877165B1 (ko) 2009-01-07
MXPA03004276A (es) 2005-04-29
DE60136095D1 (de) 2008-11-20
DK1341785T3 (da) 2009-01-26
WO2002043667A3 (en) 2002-10-10
ATE410413T1 (de) 2008-10-15
SK7212003A3 (en) 2004-03-02
PT1341785E (pt) 2009-01-16
KR20030059253A (ko) 2003-07-07
CN1561341A (zh) 2005-01-05
EP1341785A4 (en) 2004-05-12
US20020099224A1 (en) 2002-07-25
EP1341785B1 (en) 2008-10-08
JP2004514687A (ja) 2004-05-20
PL362981A1 (en) 2004-11-02

Similar Documents

Publication Publication Date Title
IS6814A (is) Vatnsrof [R(R*,R*)]-2-(4-flúorfenýl)-ß,ð-díhýdroxý-5-(1-metýletýl)-3-fenýl-4-[(fenýlamínó)karbónýl]-1H-pýrról-1-heptanónsýruestera með kalsíumhýdroxíði
BR0116785A (pt) Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediários
YU36802A (sh) Postupak za dobijanje amorfnog atorvastatina
UY24985A1 (es) Formas cristalinas hidratadas de atorvastatina forma i
YU56803A (sh) Pripremanje nekristalinskog atorvastatin-kalcijuma
ZA966043B (en) Novel process for the production of amorphous [R-(R*,R*)]-2(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acide calcium salt (2:1).
BG102186A (en) Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin)
EE200300597A (et) [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[fenüülamino)karbonüül]-1H-pürrool-1-hepta anhappe kaltsiumsoola (2:1) (atorvastatiini) kristallilised vormid
TW200724688A (en) Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof
HUP0402590A3 (en) Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)
MXPA04000889A (es) Formas cristalinas vi y vii de atorvastatina calcica.
WO2003050085A8 (en) CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1)
IL173651A0 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
NZ512207A (en) Process for producing quinolinecarbaldehyde
ZA200303974B (en) Hydrolysis of [R(R*,R*)]-2-(4-Fluorophenyl)-b,D-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic acid esters with calcium hydroxide.
CL2009001050A1 (es) Proceso de preparacion de una composicion farmaceutica que comprende obtener la sal hemicalcica del acido [r-(r*,r*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico y adicionar un portador farmaceuticamente aceptable a dicho compuesto (divisional de la solicitud 1301-03).
AU2001234058A1 (en) Form v crystalline (r-(r*,r*))-2-(4-fluorophenyl)-ss,$g(d)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1- heptanoic acid hemi calcium salt. (atorvastatin)